^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Sanvar (vapreotide)

i
Other names: RC-160, BMY-41606, Debio 8609
Associations
Trials
Company:
Bausch Health, Debiopharm, Eisai, PharmGKB
Drug class:
SSTR agonist
Associations
Trials
10ms
Octreotide and postoperative pancreatic fistula after pancreaticoduodenectomy: What we know so far? A narrative review. (PubMed, Indian J Cancer)
Most of the earlier studies used different definitions of POPF and other complications; included patients with varied pancreatic pathologies such as cancer, chronic pancreatitis, and benign lesions; surgical techniques such as pancreaticoduodenectomy, distal pancreatectomy, and other procedures; use of somatostatin and its analogs such as octreotide, lanreotide, pasireotide, and vapreotide; varied surgeon and institutional volume; and so on. Data indicate favorable role of newer somatostatin analogs, and further studies are urgently needed. The question about the efficacy of prophylactic octreotide to reduce POPF after pancreaticoduodenectomy remains open to debate.
Review • Journal
|
Sanvar (vapreotide)